EGFR and neoplasm: Consequently, ZD6474 has the potential to inhibit two key pathways in tumour growth by (i) targeting tumour growth indirectly, via inhibition of VEGF-dependent tumour angiogenesis and VEGF-dependent endothelial cell survival, and (ii) targeting tumour growth directly, via inhibition of EGFR-dependent tumour cell proliferation and survival (Figure 1).